Curis Inc (CRIS) Dividend History

Company News

• VISTA Inhibitor Clinical Trials Drug Approval Insight - GlobeNewswire

  VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from existing therapies.

  GlobeNewswire Inc.

  Featured Companies: MRK SNSE
• Top 3 Health Care Stocks That May Collapse In Q2

  As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above ...

  Benzinga

  Featured Companies: OCX RVMD
• Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

  Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

  Zacks Investment Research

  Featured Companies: MRSN
• Curis shares rise as analysts see 'the next Pharmacyclics'

  Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out target

  MarketWatch

  Featured Companies: ABBV
• Curis (CRIS) Q2 2022 Earnings Call Transcript

  CRIS earnings call for the period ending June 30, 2022.

  The Motley Fool